Back to Search
Start Over
Multiple myeloma: Available therapies and causes of drug resistance
- Source :
- Cancers, Vol 12, Iss 2, p 407 (2020), Cancers
- Publication Year :
- 2020
- Publisher :
- MDPI, 2020.
-
Abstract
- Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies. Survival outcomes have improved substantially due to the introduction of many of these drugs allied with their rational use. Nonetheless, MM patients successively relapse after one or more treatment regimens or become refractory, mostly due to drug resistance. This review focuses on the main drugs used in MM treatment and on causes of drug resistance, including cytogenetic, genetic and epigenetic alterations, abnormal drug transport and metabolism, dysregulation of apoptosis, autophagy activation and other intracellular signaling pathways, the presence of cancer stem cells, and the tumor microenvironment. Furthermore, we highlight the areas that need to be further clarified in an attempt to identify novel therapeutic targets to counteract drug resistance in MM patients. The work of our laboratory is funded by project NORTE-01-0145-FEDER-000029, supported by Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); also by FEDER?Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020?Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT?Funda??o para a Ci?ncia e a Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior in the framework of the project "Institute for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-007274)". The authors also thank ?Sociedade Portuguesa de Hematologia? for a grant to Rui Bergantim.
- Subjects :
- 0301 basic medicine
Lymphocytes / metabolism
Cancer Research
medicine.drug_class
drug response
Review
Drug resistance
Monoclonal antibody
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Cancer stem cell
Medicine
Humans
Epigenetics
RNA-Seq
Multiple myeloma
Tumor microenvironment
drug resistance
treatment
Immune System/ embryology
business.industry
Autophagy
Monocytes/ metabolism
Genomics
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
multiple myeloma
030104 developmental biology
Oncology
Organ Specificity
030220 oncology & carcinogenesis
Cancer research
Histone deacetylase
Single-Cell Analysis
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Cancers, Vol 12, Iss 2, p 407 (2020), Cancers
- Accession number :
- edsair.doi.dedup.....19f7a314309de604d9416763b0cfccf9